Pfizer Inc PFE:NYSE (Common Stock)

LastDaily Change / % ChangeDividend YieldVolumeAvg Volume (10 day)
36.64 0.06   0.16%3.50%15,787,24717.6M
Market data is delayed by at least 15 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Market is closed. Chart as of 04:00 PM ET 12/13/2017

Latest News Headlines for Pfizer Inc

Talazoparib Significantly Extends Progression-Free Survival in Phase 3 EMBRACA Trial of Patients with Metastatic Breast Cancer

or any other oncology products; whether and when such applications may be approved by regulatory authorities, which will depend on the assessment by such regulatory authorities of the benefit-risk profile suggested by the totality of the efficacy and safety information submitted, and, if approved, whether talazoparib or any such other oncology products will be commercially successful; decisions by regulatory authorities regarding labeling and other matters that could affect the availability or commercial potential of talazoparib or other oncology products; and competitive developments.

Pfizer Inc. Announces (i) Private Exchange Offer for its 6.500 per cent. Notes due 2038 Open to Certain Investors and Related Tender Offer Open to All Investors and (ii) Tender Offer for its 5.750 per cent. Notes due 2021 and Related Solicitation of Consents

Only holders that validly tender their 2021 Notes and deliver their corresponding Consents at or prior to the Early Tender and Consent Date and do not validly withdraw their 2021 Notes will be eligible to receive the Tender Total Consideration (which includes the Early Tender and Consent Payment). Holders validly tendering their 2021 Notes after the Early Tender and Consent Date and on or prior to the 2021 Notes Tender Expiration Date will only be eligible to receive the Tender Total Consideration less the Early Tender and Consent Payment. In addition, all holders that validly tender their 2021 Notes that are accepted for purchase in the 2021 Notes Tender Offer will receive a cash payment representing Accrued Interest. Holders may not tender their 2021 Notes (including following the Early Tender and Consent Date) without delivering their Consents in respect of the tendered 2021 Notes.

Updated Data from Phase 3 Trial of IBRANCE(R) (palbociclib) Plus Letrozole in ER+, HER2- Metastatic Breast Cancer Confirm Improvement in Progression-Free Survival

Avoid concurrent use of strong CYP3A inhibitors. If patients must be administered a strong CYP3A inhibitor, reduce the IBRANCE dose to 75 mg/day. If the strong inhibitor is discontinued, increase the IBRANCE dose (after 3-5 half-lives of the inhibitor) to the dose used prior to the initiation of the strong CYP3A inhibitor. Grapefruit or grapefruit juice may increase plasma concentrations of IBRANCE and should be avoided. Avoid concomitant use of strong CYP3A inducers. The dose of sensitive CYP3A substrates with a narrow therapeutic index may need to be reduced as IBRANCE may increase their exposure.

View more recent headlines

Peers Information HelpPFE Pfizer Inc vs. Peers

PFE
Pfizer Inc
12.62%
Roche Holding Ltd. (ADR)
6.34%
Novartis AG (ADR)
15.95%
-3.06%
Merck & Co., Inc.
Bayer AG (ADR)
20.29%
PFE
Pfizer Inc
3.49%
Roche Holding Ltd. (ADR)
3.37%
Novartis AG (ADR)
3.21%
Merck & Co., Inc.
3.37%
Bayer AG (ADR)
2.36%
PFE
Pfizer Inc
0.16%
Roche Holding Ltd. (ADR)
0.53%
Novartis AG (ADR)
0.24%
-0.28%
Merck & Co., Inc.
-0.05%
Bayer AG (ADR)
Compare these stocks

Latest Annual and Quarterly SEC Filings

More Filings
10-K

This report contains detailed information about the company's business finances and management.

10-Q

Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines, as well as products for consumer healthcare. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

http://www.pfizer.com

Loading...

expand, down-facing arrow indicating expanded view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open36.57
Previous Close36.58
Day High36.80
Day Low36.47
52 Week High12/12/2017 | 36.82
52 Week Low1/24/2017 | 30.90
% Off 52 Week High-0.49%
% Off 52 Week Low18.58%
Beta (5 Yr)1.0
Volatility Avg12/13/2017 | 11.24
10-Day Avg. Volume17,621,825
Market data is delayed by at least 15 minutes.

collapse, right-facing arrow indicating collapsed view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)10/1/2017 | 1.63
P/E Ratio10/1/2017 | 22.2
Market CapMega Cap | 218.40B
Shares Outstanding5.96B
Float6.0B

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield3.50%
Ex-Date11/9/2017
Dividend Announcement9/27/2017
Date of Record11/10/2017
Payable$0.32 - QRTR
Payable Date12/1/2017

collapse, right-facing arrow indicating collapsed view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short50.04M
Short Ratio3.8
Short % of Float--
As of 11/30/2017
The performance data quoted represents past performance. Past performance does not guarantee future results. Current performance may be lower or higher than the performance quoted. Investment return and principal value of an investment will fluctuate and when redeemed, the investment may be worth more or less than their original cost.
The research, tools, and information provided will not include every security available to the public.